Steve Sideris
Overview
Explore the profile of Steve Sideris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
1512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hanan E, Braun M, Heald R, MacLeod C, Chan C, Clausen S, et al.
J Med Chem
. 2022 Dec;
65(24):16589-16621.
PMID: 36455032
Small molecule inhibitors that target the phosphatidylinositol 3-kinase (PI3K) signaling pathway have received significant interest for the treatment of cancers. The class I isoform PI3Kα is most commonly associated with...
2.
Kahn-Kirby A, Amagata A, Maeder C, Mei J, Sideris S, Kosaka Y, et al.
PLoS One
. 2019 Mar;
14(3):e0214250.
PMID: 30921410
Background: Mitochondrial disease is a family of genetic disorders characterized by defects in the generation and regulation of energy. Epilepsy is a common symptom of mitochondrial disease, and in the...
3.
Purkey H, Robarge K, Chen J, Chen Z, Corson L, Ding C, et al.
ACS Med Chem Lett
. 2016 Oct;
7(10):896-901.
PMID: 27774125
A series of trisubstituted hydroxylactams was identified as potent enzymatic and cellular inhibitors of human lactate dehydrogenase A. Utilizing structure-based design and physical property optimization, multiple inhibitors were discovered with...
4.
Chan B, Hanan E, Bowman K, Bryan M, Burdick D, Chan E, et al.
J Med Chem
. 2016 Aug;
59(19):9080-9093.
PMID: 27564586
Inhibitors targeting the activating mutants of the epidermal growth factor receptor (EGFR) have found success in the treatment of EGFR mutant positive non-small-cell lung cancer. A secondary point mutation (T790M)...
5.
Boudreau A, Purkey H, Hitz A, Robarge K, Peterson D, Labadie S, et al.
Nat Chem Biol
. 2016 Aug;
12(10):779-86.
PMID: 27479743
Metabolic reprogramming in tumors represents a potential therapeutic target. Herein we used shRNA depletion and a novel lactate dehydrogenase (LDHA) inhibitor, GNE-140, to probe the role of LDHA in tumor...
6.
Heffron T, Ndubaku C, Salphati L, Alicke B, Cheong J, Drobnick J, et al.
ACS Med Chem Lett
. 2016 Apr;
7(4):351-6.
PMID: 27096040
Inhibition of phosphoinositide 3-kinase (PI3K) signaling is an appealing approach to treat brain tumors, especially glioblastoma multiforme (GBM). We previously disclosed our successful approach to prospectively design potent and blood-brain...
7.
Heald R, Bowman K, Bryan M, Burdick D, Chan B, Chan E, et al.
J Med Chem
. 2016 Mar;
59(6):2848.
PMID: 26967667
No abstract available.
8.
Bryan M, Burdick D, Chan B, Chen Y, Clausen S, Dotson J, et al.
ACS Med Chem Lett
. 2016 Jan;
7(1):100-4.
PMID: 26819674
The rapid advancement of a series of noncovalent inhibitors of T790M mutants of EGFR is discussed. The optimization of pyridone 1, a nonselective high-throughput screening hit, to potent molecules with...
9.
Heffron T, Heald R, Ndubaku C, Wei B, Augistin M, Do S, et al.
J Med Chem
. 2016 Jan;
59(3):985-1002.
PMID: 26741947
Inhibitors of the class I phosphoinositide 3-kinase (PI3K) isoform PI3Kα have received substantial attention for their potential use in cancer therapy. Despite the particular attraction of targeting PI3Kα, achieving selectivity...
10.
Hanan E, Baumgardner M, Bryan M, Chen Y, Eigenbrot C, Fan P, et al.
Bioorg Med Chem Lett
. 2015 Dec;
26(2):534-539.
PMID: 26639762
The treatment of epidermal growth factor receptor (EGFR)-driven non-small cell lung cancers with the T790M resistance mutation remains a significant unmet medical need. We report the identification of 4-aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as...